By G HossainPosted on January 7, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs The acquisition is centered on Dark Blue Therapeutics’ small-molecule degrader of the MLLT1 and MLLT3 proteins, which is being tested for acute myeloid leukemia. Amgen Makes up to $840M Cancer Play With Dark Blue Takeover Post navigation BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight WalletsCorsera Raises $80M as First Preventative Heart Disease Program Moves Into Clinic